Analysts Raise Ultragenyx Price Targets After FAYUVI Approval: Cantor Fitzgerald and Canaccord to $39, Citi to $32, Morgan Stanley to $20
Several analysts raised their Ultragenyx price targets on Friday, September 18, 2026, a day after the FDA's standard full approval of FAYUVI for the neurologic manifestations of Sanfilippo syndrome type A (MPS IIIA) in children. Cantor Fitzgerald moved to $39 from $33 with an Overweight rating, raised its probability of success to 100% from 90%, and valued the MPS IIIA opportunity at about $12 to $13 per share; Canaccord Genuity moved to $39 from $37 (Buy), Morgan Stanley to $20 from $18 (Equal Weight), and Citi to $32. Cantor also estimated that the priority review voucher Ultragenyx received with the approval, together with another voucher the company already holds, could bring in about $400 million if sold. Ultragenyx expects FAYUVI to be available to ship to qualified treatment centers within 30 to 60 days.